A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen. METHODS: Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy. RESULTS: A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 received the high-dose regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard regimen and 3.0% of patients receiving the high-dose regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard regimen and 77.9% of patients who received the high-dose regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups. CONCLUSIONS: Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“A study comparing a triple daily dose of caspofungin (150-mg daily) versus standard 50-mg daily dosing found no advantage for the higher dose [24].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
In the citing paper
“Taken together, these studies show that higher than standard doses of echinocandins, while generally well tolerated, do not improve patient outcomes in most clinical scenarios.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“Adult patients (age, 18 years) were eligible for inclusion if they had both clinical and microbiological evidence of invasive candidiasis at a sterile site, in accordance with the criteria for proven invasive candidiasis described by the Mycosis Study Group and the European Organization for the Research and Treatment…”
MethodComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · cited 6×
“Follow-up procedures were as described elsewhere [6].”
BackgroundMethodResultInfluentialSelf-citationPractice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · cited 3×
“This was a multicenter, randomized, double-blind study conducted from January 2006 through January 2008 at 38 sites in North and South America, Europe, and Asia to evaluate the safety, tolerability, and efficacy of caspofungin at a dosage of 50 mg/day (after a 70-mg loading dose on day 1 of treatment), compared with c…”
MethodInfluentialAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationCandidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationEpidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species
Jarvis, W. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1526 · Cited by 636 · cited 2×
“nosocomial pathogens overall [1].”
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
Background
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationTissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
BackgroundSelf-citationMaertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Self-citationPfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
“CAS09-1786 2009 Georgia NA 2 16 2 S663P(2)”
BackgroundInfluentialEchinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“The echinocandins also exhibit prolonged postantifungal effects (PAFE) against Candida spp.[55,119,127,129] The PAFE for caspofungin against C. albicans was noted to be >12 hours when concentrations exceeded the MIC.”
BackgroundResultInfluentialPfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 334
McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
Candidemia and invasive candidiasis in adults: A narrative review
Antinori, S., Milazzo, L., Sollima, S., Galli, M., & Corbellino, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.029 · Cited by 257
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
“100 mg/day) showed a trend towards improved efficacy in subgroups of patients (APACHE II score >20, neutropenia) andmight be used in selected patients [19, 36, 128].”
MethodNucci, M., Anaissie, E., Betts, R. F., Dupont, B. F., Wu, C., Buell, D. N., Kovanda, L., & Lortholary, O. (2010) · Clinical Infectious Diseases · doi:10.1086/653935 · Cited by 228
“Of the 6 RCTs of candidemia that examined the effect of CVC removal on outcome [6, 7, 16, 20, 27, 28], 4 trials [6, 16, 20, 27] failed to identify a beneficial role for CVC removal.”
BackgroundSelf-citationOcular manifestations of candidemia
Oude Lashof, A. M. L., Rothova, A., Sobel, J. D., Ruhnke, M., Pappas, P. G., Viscoli, C., Schlamm, H. T., Oborska, I. T., Rex, J. H., & Kullberg, B. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir355 · Cited by 218
Treatment of Endogenous Fungal Endophthalmitis: Focus on New Antifungal Agents
Riddell, J., Comer, G. M., & Kauffman, C. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq204 · Cited by 217
Cornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., Thompson, G. R., & for the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 215
Clinical hepatotoxicity associated with antifungal agents
Kyriakidis, I., Tragiannidis, A., Munchen, S., & Groll, A. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1270264 · Cited by 187
“nuations were similar between groups [54].”
BackgroundWang, J.-L., Chang, C.-H., Young-Xu, Y., & Chan, K. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01657-09 · Cited by 167
Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163
Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153
“Higher dosages of caspofungin (up to 150mg/d) have been studied in clinical trials suggesting a higher efficacy in subgroups of patients and a dose-related response [60; 61].”
BackgroundEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson, G. R., Jenks, J. D., Baddley, J. W., Lewis, J. S., Egger, M., Schwartz, I. S., Boyer, J., Patterson, T. F., Chen, S. C. ‐., Pappas, P. G., et al. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-23 · Cited by 165
Self-citationAntifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“Clinical studies in which echinocandin dose levels have been escalated have not identified a paradoxical effect (Pappas et al. 2007; Betts et al. 2009; Shields et al. 2011; Szilagyi et al. 2012; Andes et al. 2013; Elefanti et al. 2013).”
BackgroundEchinocandins: production and applications
Emri, T., Majoros, L., Tóth, V., & Pócsi, I. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4761-9 · Cited by 123
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“parapsilosis in the standard dose regimen (50 mg/day) versus the high-dose regimen (150 mg/day) (61% versus 91%, respectively) [24].”
BackgroundEpidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Amornphimoltham, P., Yuen, P. S. T., Star, R. A., & Leelahavanichkul, A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05581-y · Cited by 109
Mellinghoff, S. C., Hoenigl, M., Koehler, P., Kumar, A., Lagrou, K., Lass‐Flörl, C., Meis, J. F., Menon, V., Rautemaa‐Richardson, R., & Cornely, O. A. (2018) · Mycoses · doi:10.1111/myc.12746 · Cited by 99
Rueda, C., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00946-13 · Cited by 98
“Some clinical studies have demonstrated that high caspofungin doses can be tolerated (54, 55), although those studies did not provide any evidence of an in vivo paradoxical effect.”
BackgroundAntifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 109
The eagle effect and antibiotic-induced persistence: two sides of the same coin?
Prasetyoputri, A., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2018.10.007 · Cited by 101
Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries
Kaur, H., & Chakrabarti, A. (2017) · Journal of Fungi · doi:10.3390/jof3030041 · Cited by 93
Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05134-11 · Cited by 93
“In patients with candidemia and invasive candidiasis, the safety and tolerability of caspofungin 150 mg once daily were comparable to those of the 50-mg standard dose (2, 20).”
BackgroundMetal Nanoparticles to Combat Candida albicans Infections: An Update
do Carmo, P. H. F., Garcia, M. T., Figueiredo-Godoi, L. M. A., Lage, A. C. P., da Silva, N. S., & Junqueira, J. C. (2023) · Microorganisms · doi:10.3390/microorganisms11010138 · Cited by 91
Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 88
“Cure Caspofungin, Micafungin L-AmB Fluconazole/ Voriconazole c-AmB/ABLC/ABCD A A C D It It III I (71,73) (87,128,133,137)”
BackgroundInvasive fungal infections in patients with cancer in the Intensive Care Unit
Sipsas, N. V., & Kontoyiannis, D. P. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.11.017 · Cited by 81
Chen, S. C., Sorrell, T. C., Chang, C. C., Paige, E. K., Bryant, P. A., & Slavin, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12597 · Cited by 88
Invasive Fungal Infections in the Intensive Care Unit
Ostrosky-Zeichner, L., & Al-Obaidi, M. (2017) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2017.05.005 · Cited by 76
“A comparison of caspofungin at a high dose of 150 mg daily dose versus a regular dose of 50 mg daily (after a loading dose of 70 mg) did not show significant difference in outcome or adverse event incidence.(38) Although micafungin was noninferior compared with liposomal amphotericin B, with a success rate of 89.”
ResultRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
European expert opinion on the management of invasive candidiasis in adults
Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Billé, J., Calandra, T., Cuenca‐Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03615.x · Cited by 78
“parapsilosis than for other Candida species [40,42], and there are reports of increased clinical failure and persistence of infection with this species [20,22,25,43–45].”
BackgroundSelf-citationEchinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 67
Overview of treatment options for invasive fungal infections
Pound, M. W., Townsend, M. L., Dimondi, V., Wilson, D., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 70
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 74
Breakthrough invasive mould infections in patients treated with caspofungin
Pang, K.-A. P., Godet, C., Fekkar, A., Scholler, J., Nivoix, Y., Letscher‐Bru, V., Massias, L., Kauffmann‐Lacroix, C., Elsendoorn, A., Uzunov, M., et al. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.12.015 · Cited by 69
Self-citationShields, R. K., Nguyen, M. H., Du, C., Press, E., Cheng, S., & Clancy, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-10 · Cited by 65
“Echinocandins are well tolerated in humans at up to three times the standard doses (4), a circumstance that has created interest in exploring the use of high-dose regimens to maximize clinical efficacy.”
BackgroundInfluentialCaspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes
Song, J. C., & Stevens, D. A. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1068271 · Cited by 61
“Off-label dosing Higher caspofungin dosages ranging from 70 mg/d to 200 mg/d have been evaluated in studies that included adult patients requiring therapy for invasive candidiasis or invasive aspergillosis (Betts et al., 2009; Cornely et al., 2007, 2011; Herbrecht et al., 2010; Maertens et al., 2006; Raad et al., 2008…”
BackgroundInfluentialLow Caspofungin Exposure in Patients in Intensive Care Units
van der Elst, K. C. M., Veringa, A., Zijlstra, J. G., Beishuizen, A., Klont, R., Brummelhuis-Visser, P., Uges, D. R. A., Touw, D. J., Kosterink, J. G. W., van der Werf, T. S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01582-16 · Cited by 64
“particularly in ICU patients and the caspofungin exposure was not measured (38).”
BackgroundCaspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 60
“In fact, a recent study demonstrated that daily doses of caspofungin of 150 mg, or three times the recommended daily dose of 50 mg, were safe and well tolerated (3).”
Treatment ofPneumocystis jiroveciipneumonia in HIV-infected patients: a review
Huang, Y., Yang, J.-J., Lee, N., Chen, G., Ko, W., Sun, H., & Hung, C. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1364991 · Cited by 70
“9%) and aspartate transaminase level (2–4%) [232].”
Rueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58
Healey, K. R., Nagasaki, Y., Zimmerman, M., Kordalewska, M., Park, S., Zhao, Y., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-17 · Cited by 57
Würthwein, G., Cornely, O. A., Trame, M. N., Vehreschild, J. J., Vehreschild, M. J. G. T., Farowski, F., Müller, C., Boos, J., Hempel, G., Hallek, M. J., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01912-12 · Cited by 59
Pitman, S. K., Drew, R. H., & Perfect, J. R. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.607811 · Cited by 54
“No differences were noted in safety, overall response or mortality at 8 weeks between the two regimens [53].”
BackgroundCurrent therapeutic approaches to fungal infections in immunocompromised hematological patients
Pagano, L., Caira, M., Valentini, C. G., Posteraro, B., & Fianchi, L. (2010) · Blood Reviews · doi:10.1016/j.blre.2009.11.003 · Cited by 54
DeJarnette, C. A., Luna-Tapia, A., Estredge, L. R., & Palmer, G. E. (2020) · mSphere · doi:10.1128/msphere.00374-20 · Cited by 54
We can do better: a fresh look at echinocandin dosing
Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx448 · Cited by 46
Glöckner, A. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-167 · Cited by 52
“a recent randomized trial compared caspofungin at elevated dosage (150 mg/d) versus standard-dose therapy in patients with proven invasive Candida infections, mostly candidemia [43].”
BackgroundAnalyzing candidemia guideline adherence identifies opportunities for antifungal stewardship
Mellinghoff, S. C., Hartmann, P., Cornely, F. B., Knauth, L., Koehler, F. C., Köhler, P., Krause, C., Kronenberg, C., Kranz, S.-L., Menon, V. P., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3285-8 · Cited by 49
Martial, L. C., Brüggemann, R. J. M., Schouten, J. A., van Leeuwen, H. J., van Zanten, A. R. H., de Lange, D. W., Muilwijk, E. W., Verweij, P. E., Burger, D. M., Aarnoutse, R. E., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0347-2 · Cited by 45
“Low exposure to caspofungin might result in clinical failure; high exposure, on the other hand, does not appear to lead to safety precautions: caspofungin has an overall favorable safety profile, and therapy with 150 mg daily is well-tolerated in patients with invasive candidiasis [35–37].”
Hiemenz, J., RAAD, I. I., Maertens, J., Hachem, R. Y., Saah, A. J., Sable, C. A., Chodakewitz, J., Severino, M. E., Saddier, P., Berman, R. S., et al. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1013-0 · Cited by 47
Impact of special patient populations on the pharmacokinetics of echinocandins
Muilwijk, E. W., Lempers, V. J. C., Burger, D. M., Warris, A., Pickkers, P., Aarnoutse, R. E., & Brüggemann, R. J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1028366 · Cited by 49
“are mild and rarely lead to treatment discontinuation and appear not to be dose-dependent [11,41].”
BackgroundPotential Microbiological Effects of Higher Dosing of Echinocandins
Steinbach, W. J., Lamoth, F., & Juvvadi, P. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ725 · Cited by 41
“(150 mg/day) included 204 adult patients with invasive candidiasis [35].”
BackgroundRoger, C., Wallis, S. C., Müller, L., Saïssi, G., Lipman, J., Brüggemann, R. J. M., Lefrant, J., & Roberts, J. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0495-z · Cited by 45
Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 45
Overview of antifungal dosing in invasive candidiasis
Pea, F., & Lewis, R. E. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 42
Franconi, I., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9121188 · Cited by 46
“Such conditions could be explained, as the drug concentration levels obtained in vivo might not be as high as those that trigger this in vitro phenomenon [101,103].”
BackgroundAn Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2013) · Infection · doi:10.1007/s15010-013-0558-0 · Cited by 49
Colombo, A. L., Ngai, A. L., Bourque, M., Bradshaw, S. K., Strohmaier, K. M., Taylor, A. F., Lupinacci, R. J., & Kartsonis, N. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-09 · Cited by 41
“Race Caucasian 41 (76) 7 (78) 7 (70) 2 (40) 45 (63) 40 (62) 141 (67) 116 (69) Black 4 (7) 2 (22) 1 (10) 1 (20) 7 (10) 10 (15) 24 (11) 15 (9) Asian 2 (4) 10 (14) 11 (17) 23 (11) 9 (5) Hispanic 6 (11) 2 (20) 1 (20) 9 (13) 3 (5) 21 (10) 20 (12) Other 1 (2) 1 (20) 1 (1) 3 (1) 7 (4)”
BackgroundResultSelf-citationCritical appraisal beyond clinical guidelines for intraabdominal candidiasis
Maseda, E., Martín‐Loeches, I., Zaragoza, R., Pemán, J., Fortün, J., Grau, S., Aguilar, G., Varela, M., Borges-Sa, M., Giménez, M.-J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04673-6 · Cited by 40
“However, no significant differences in efficac-ity were found when compared with standard doses in clinical trials [76, 77], a fact which could be related to the well-described limitation of this type of studies to include enough patients infected by isolates exhibiting high MIC values (patients…”
ResultKim, H. Y., Baldelli, S., Märtson, A., STOCKER, S. L., Alffenaar, J. C., Cattaneo, D., & Marriott, D. J. E. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000931 · Cited by 42
Dosing of antifungal agents in obese people
Payne, K. D., & Hall, R. G. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1128822 · Cited by 39
“[52] Caspofungin doses up to 200 mg/day have been administered, with no reports of dose-limiting toxicity.[53,54]”
BackgroundChen, L., Li, Y., Yue, Q., Loksztejn, A., Yokoyama, K., Felix, E., Liu, X., Zhang, N., An, Z., & Bills, G. F. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00604 · Cited by 38
Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients
Li, C., Sun, P. G., Dong, Y., Bi, S., Desai, R., Dockendorf, M. F., Kartsonis, N. A., Ngai, A. L., Bradshaw, S. K., & Stone, J. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00905-10 · Cited by 37
“) echinocandin antifungal agent that inhibits the synthesis of -(1,3)-D-glucan, an essential component of the cell wall of many pathogenic fungi, including Candida and Aspergillus species.”
BackgroundSelf-citationPersistent Candidemia: Causes and Investigations
Nucci, M. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0039-1 · Cited by 37
“[ 25 ] 2009 Prospective, RCT, adults with candidemia 197: 102 caspofungin (50 mg/d), 95 caspofungin (150 mg/d) Day ten and at the end of treatment Persistently positive blood culture at the end of treatment 15 of 197 (8%): 12% caspofungin (50 mg/d), 3% caspofungin (150 mg/d) (P=0.02) Not reported”
BackgroundSelf-citationCandidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento
Cervera, C. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.003 · Cited by 48
Invasive candidiasis: update on current pharmacotherapy options and future perspectives
Tragiannidis, A., Tsoulas, C., Kerl, K., & Groll, A. H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.805204 · Cited by 40
“2 Caspofungin Caspofungin has been studied in the treatment of IC, esophageal candidiasis, febrile neutropenia and invasive aspergillosis [91-100].”
BackgroundSafety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants
Migoya, E. M., Mistry, G. C., Stone, J. A., Comisar, W. A., Sun, P. G., Norcross, A., Bi, S., Winchell, G. A., Ghosh, K., Uemera, N., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374853 · Cited by 32
“For comparison, caspofungin 150 mg once daily has been well tolerated in patients with invasive candidiasis.(17) In conclusion, the results of this study suggest that caspofungin 100 mg given once daily for up to 21 days is generally safe and well tolerated and displays a pharmacokinetic profile consistent with that o…”
ResultInvasive fungal infections in liver diseases
Barros, N., Rosenblatt, R. E., Phipps, M. M., Fomin, V. G., & Mansour, M. K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000216 · Cited by 35
“Higher than recommended dosing is not shown to be superior to standard dosing for Candida spp.[117] Amphotericin has similar efficacy to echinocandins but more side effects, yet it remains an alternative if echinocandins are not available or are contraindicated.”
BackgroundSuárez, F., Olivier, G., Garcia‐Hermoso, D., Randriamalala, E., Ghez, D., Bruneau, J., Kauffmann‐Lacroix, C., Bougnoux, M., & Lortholary, O. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01213-10 · Cited by 32
“sis of -(1,3)-D-glucan, a major component of the fungal cell”
BackgroundKurland, S., Furebring, M., Löwdin, E., Eliasson, E., Nielsen, E. I., & Sjölin, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02466-18 · Cited by 32
“Higher daily doses of up to 200 mg of caspofungin have been studied and are reported as well tolerated (26, 27).”
BackgroundAndes, D. R., Brüggemann, R. J. M., Flanagan, S., Lepak, A. J., Lewis, R. E., Ong, V. S., Rubino, C. M., & Sandison, T. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae415 · Cited by 35
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 31
Caspofungin: a review of its characteristics, activity, and use in intensive care units
Hashemian, S. M. R., Farhadi, T., & Velayati, A. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1794817 · Cited by 31
Brüggemann, R. J. M., van der Velden, W. J. F. M., Knibbe, C. A. J., Colbers, A. P. H., Hol, S., Burger, D. M., Donnelly, J. P., & Blijlevens, N. M. A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku477 · Cited by 33
Essentials in Candida bloodstream infection
Mellinghoff, S. C., Cornely, O. A., & Jung, N. (2018) · Infection · doi:10.1007/s15010-018-1218-1 · Cited by 32
Management of Invasive Candidiasis in the Intensive Care Unit
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Drugs · doi:10.2165/10898550-000000000-00000 · Cited by 30
“Different dosing regimens were compared in two randomized trials: micafungin dosed at 150mg/day versus 100mg/day([84]) and caspofungin dosed at 70mg on day 1 then 50mg/day versus 150mg/day.([112]) Although neither study was adequately powered, efficacy was similar and the different drug doses were equally well tolerat…”
Extended Dosing Regimens for Fungal Prophylaxis
Lehrnbecher, T., Bochennek, K., Klingebiel, T. E., Gastine, S., Hempel, G., & Groll, A. H. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-19 · Cited by 30
“…QD in 46 adults with probable/proven invasive aspergillosis Linear pharmacokinetics with dose-proportional increases in AUC; MTD criteria not reached Betts et al., 2009 (57) Caspofungin at 50 mg QD vs 150 mg QD in 204 adults with invasive candidiasis Not investigated; no safety issues at the…”
BackgroundThe eagle-like effect of echinocandins: what’s in a name?
Vanstraelen, K., Lagrou, K., Maertens, J., Wauters, J., Willems, L., & Spriet, I. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.841543 · Cited by 28
Neoh, C. F., Slavin, M. A., Chen, S. C. ‐., Stewart, K., & Kong, D. C. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.010 · Cited by 32
Ngai, A. L., Bourque, M. R., Lupinacci, R. J., Strohmaier, K. M., & Kartsonis, N. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.008 · Cited by 27
“Patients with invasive candidiasis CAS was evaluated in three studies involving patients with invaive candidiasis: two randomised double-blind studies in which the ajority (>80%) of patients had candidaemia [3,4]; and one openabel non-comparative study in patients with non-blood sites of nfection [5].”
BackgroundMethodResultInfluentialSelf-citationEchinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Charlier, C., El Sissy, C., Bachelier-Bassi, S., Scemla, A., Quesne, G., Sitterlé, E., Legendre, C., Lortholary, O., & Bougnoux, M.-E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02265-15 · Cited by 26
“The peak flucytosine serum concentration at day 4 was 57 mg/liter (9).”
BackgroundFundament and Prerequisites for the Application of an Antifungal TDM Service
Brüggemann, R. J. M., & Aarnoutse, R. E. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0224-3 · Cited by 30
“Large clinical trials need to incorporate pharmacokinetic research instead of only investigating the effect of dose on outcome [38, 43–45].”
BackgroundIdentification of Inhibitors of Fungal Fatty Acid Biosynthesis
DeJarnette, C. A., Meyer, C. J., Jenner, A. R., Butts, A., Peters, T. L., Cheramie, M. N., Phelps, G. A., Vita, N. A., Loudon, V. C., Lee, R. E., Jr., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00404 · Cited by 25
Vena, A., Bovis, F., Tutino, S., Barbone, A. S., Mezzogori, L., Ponzano, M., Taramasso, L., Baldi, F., Dettori, S., Labate, L., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac656 · Cited by 26
Yang, Q., Wang, T., Xie, J., Wang, Y., Zheng, X., Chen, L., Li, Y., Meng, T., & Dong, Y. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.02.004 · Cited by 24
Livermore, J., Felton, T., Abbott, J., Sharp, J., Goodwin, J., Gregson, L., Warn, P. A., Howard, S. J., & Hope, W. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-12 · Cited by 24
Lewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23
Domingos, E. L., Vilhena, R. D. O., dos Santos, J. M. M. F., Fachi, M. M., Böger, B., Adam, L. M., Tonin, F. S., & Pontarolo, R. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106614 · Cited by 23
Garbez, N., Mbatchi, L., Wallis, S. C., Müller, L., Lipman, J., Roberts, J. A., Lefrant, J., & Roger, C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01062-6 · Cited by 22
Metadata
- Authors
- Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., Strohmaier, K. M., Tucker, K. A., Taylor, A. F., Kartsonis, N. A., & Caspofungin High‐Dose Study Group
- Affiliations
- University of Rochester (US)
- Lehigh Valley Hospital (US)
- VA North Texas Health Care System (US)
- Hôpitaux Universitaires de Strasbourg (FR)
- University of Minnesota (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Kartsonis, Nicholas A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-15
- Volume
- 48
- Issue
- 12
- Pages
- 1676-1684
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168334830
- Cited by
- 214
- References
- 17
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 13 · 2019: 10 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 12 · 2014: 6 · 2013: 17 · 2012: 19
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, invasive candidiasis, antifungal therapy, drug safety, drug-related adverse events, microbiological clearance, treatment efficacy, phlebitis, liver enzymes, mortality, neutropenia, adult patients, echinocandins, fluconazole, amphotericin B
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Alkaline Phosphatase, Antifungal Agents, Aspartate Aminotransferases, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Phlebitis, Treatment Outcome, Echinocandins, Lipopeptides, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.